Long-term safety study for dry AMD with geographic atrophy
Part of Eyes & vision clinical trials.
This study continues to check the safety of the drug vonaprument (ANX007) for people with dry age-related macular degeneration (AMD) that has geographic atrophy (a type of advanced dry AMD). It is for people who finished the earlier ARCHER II study and are willing to keep receiving the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have dry AMD with geographic atrophy.
- You completed the ARCHER II study (NCT06510816).
- You did not stop your assigned treatment (injection or sham) before the 24-month visit in that study.
- You have no new health problems that would make this study unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests an oral medication called BRX011 taken once daily for geographic atrophy, a progressive form of advanced dry age-related macular degeneration. The goal is to see if it is safe and can help slow vision loss.
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.